Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at-risk pre-term infants

Document first published:
Page updated:
Topic:
Publication type:

These documents set out the interim clinical commissioning position for passive immunisation with palivizumab against respiratory syncytial virus (RSV) in at-risk pre-term infants.

Summary

Letter from James Palmer, National Medical Director, Specialised Services, NHS England and NHS Improvement.

Published 20 October 2020.